Tech Session VII: Nanomedicine and Nanoscale Delivery (Focus: Bioengineering)
Short-Chain Brushed PEGylation Evades Anti-PEG Immunity to Enhance Nanomedicine Safety and Efficacy
Friday, July 18, 2025
9:38 AM – 9:49 AM EDT
Introduction: Polyethylene glycol (PEG) has revolutionized nanomedicine by enhancing the pharmacokinetics and biocompatibility of nanoparticles. However, the rising prevalence of anti-PEG antibodies has emerged as a critical challenge, compromising the efficacy and safety of PEGylated therapeutics. To address this, we developed short-chain brushed PEGylation (PEG500) of mesoporous silica nanoparticles (MSNs) to mitigate immune recognition while preserving key therapeutic advantages.
Learning Objectives:
At the completion of this activity, participants will know
Describe anti-PEG antibody effects on pharmacokinetics and safety.
Evaluate short-chain PEGylation for reducing immunogenicity.
Analyze MSN-PEG500's clinical translation in drug delivery.
